GSEP
AUPH icon

Golden State Equity Partners’s Aurinia Pharmaceuticals AUPH Stock Holding History

Golden State Equity Partners’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-900
Closed -$6.6K – 470
2024
Q3 		$6.6K Buy
+900
New +$5.58K ﹤0.01% 619

Other funds holding AUPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Golden State Equity Partners's AUPH Position: Q4 2024 in Review

Golden State Equity Partners sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2024, closing a stake of 900 shares — an estimated $6.6K sold.

Golden State Equity Partners first reported a position in AUPH in Q3 2024 and held it in 1 quarter. The position peaked at $6.6K in Q3 2024. 200 funds tracked by Wall St. Rank hold AUPH as of Q4 2024.

  • Golden State Equity Partners reported no remaining Aurinia Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Golden State Equity Partners sold 900 Aurinia Pharmaceuticals shares in Q4 2024, an estimated $6.6K.
  • Golden State Equity Partners first reported a position in Aurinia Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Golden State Equity Partners's Aurinia Pharmaceuticals position peaked at $6.6K in Q3 2024.
  • 200 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2024.

Based on Golden State Equity Partners's 13F filing for Q4 2024, filed 24 Jan 2025.